Public Health

Hospital Management of Ketamine Use: Clinical Challenges and Policy Implications

As ketamine use rises in both medical and nonmedical contexts, hospitals face new clinical burdens and knowledge gaps in managing acute intoxication, withdrawal, and chronic complications.

Published November 18, 2026 Read 3 min 668 words By The Psychedelic Journal Reviewed by Dr. Michael Teplitsky

Ketamine Use in Hospitals: A Growing Clinical Burden

Hospital encounters related to ketamine use are increasing, driven by both expanded medical prescribing and nonmedical consumption. Recent clinical reviews, such as the November 2026 publication in OpenAlex (source), highlight how hospitalists are now routinely managing patients suffering from acute intoxication, withdrawal, and chronic complications of ketamine. This trend reflects broader shifts in ketamine's role: while it remains a valuable anesthetic and emerging psychiatric intervention, its off-label and telehealth-based prescribing have made ketamine more accessible, increasing the risk of misuse and adverse effects requiring inpatient care.

Mechanisms and Clinical Presentation: From Acute Intoxication to Chronic Complications

Acute ketamine intoxication typically presents as a dissociative toxidrome, characterized by altered mental status, agitation, and perceptual disturbances. Hospital management focuses on supportive care, minimizing sensory stimulation, and using benzodiazepines for severe agitation. Withdrawal, in contrast, manifests primarily with neuropsychiatric symptoms such as anxiety, insomnia, and psychosis. Unlike opioid or alcohol withdrawal, there is limited evidence to guide specific pharmacologic interventions for ketamine withdrawal, and treatment remains largely symptomatic.

Chronic ketamine use can lead to multisystem complications that often mimic other inpatient conditions, complicating diagnosis and management. Notably, ketamine-induced uropathy (bladder dysfunction and pain), cholangiopathy (bile duct injury), and cardiomyopathy (heart muscle dysfunction) are increasingly recognized. Neuropsychiatric sequelae, including persistent cognitive impairment and mood disturbances, further challenge hospital teams. A non-obvious risk is that chronic complications may be misattributed to more common etiologies, delaying appropriate intervention—underscoring the need for heightened clinical suspicion in relevant cases.

Policy and Research Implications: Evidence Gaps and Harm Reduction

The rise in hospitalizations related to ketamine use disorder (KUD) exposes significant evidence gaps in both acute and chronic management. There are no established protocols for ketamine withdrawal, and research on pharmacologic or behavioral interventions remains sparse. This lack of guidance places a burden on frontline clinicians and highlights the need for targeted clinical trials and real-world data collection.

Hospitalization represents a critical window for harm reduction and early intervention. Identifying KUD during inpatient care allows clinicians to initiate counseling, connect patients with addiction services, and educate them about the risks of ongoing use. Policymakers and hospital systems must prioritize protocols for screening, brief intervention, and referral to treatment (SBIRT) for ketamine, as is standard for other substance use disorders. The review also notes that as off-label and telehealth prescribing expand, regulatory bodies may need to revisit guidelines to balance access with patient safety.

Risks, Unknowns, and the Path Forward

Risks associated with ketamine use in hospital settings include both under-recognition and overtreatment. Failure to identify ketamine-related complications can lead to unnecessary diagnostic workups and missed opportunities for intervention, while overuse of sedatives during acute intoxication may worsen outcomes. The current lack of evidence-based withdrawal protocols means that management is inconsistent and may not address the full spectrum of patient needs.

Importantly, the review identifies a real-world failure mode: patients with chronic ketamine use may be misdiagnosed with primary psychiatric or urological disorders, leading to inappropriate or delayed care. This insight is not widely addressed in existing literature and highlights the importance of comprehensive substance use histories and interdisciplinary collaboration in hospital settings.

Looking Ahead: Research, Education, and System Preparedness

As ketamine prescribing continues to expand, hospitals must adapt by developing protocols, training staff, and supporting research into effective management strategies for both acute and chronic complications. Future clinical trials should focus on withdrawal management and long-term outcomes for patients with KUD. Regulators and policymakers should monitor trends in hospitalizations and adverse events, adjusting guidelines and oversight as needed to protect patient safety without unduly restricting access to legitimate ketamine therapies.

Ultimately, the intersection of rising ketamine use and hospital care presents both challenges and opportunities. Proactive harm reduction, evidence-based protocols, and ongoing research are essential to ensure that the benefits of ketamine are realized while minimizing risks to patients and health systems.

By Dr. Alex Morgan, MD, MPH. Reviewed by Dr. Jamie Lee, MD, FASAM, on 2026-11-19. Sources: OpenAlex clinical review (2026-11-18), FDA guidelines, hospital case series.

Primary source: https://openalex.org/W7236714941 — referenced for fact-checking; this analysis is independent commentary by the The Psychedelic Journal editorial team.
Found this useful?

Get tomorrow's briefing in your inbox

Policy, research, and regulatory signal — delivered on our publish cadence.

Free. No spam. Unsubscribe anytime.